Gilead Sciences Inc (GILD) reported earnings per share (EPS) of $2.47 for the third quarter of fiscal 2025, surpassing analysts' expectations of $2.17 by $0.30. Revenue reached $7.8 billion, exceeding the forecast of $7.6 billion. This performance reflects the company's robust operational capabilities.
The company will host an earnings conference call to discuss these results and provide further insights into its business performance. Gilead, based in Foster City, California, specializes in research and development of medicines for unmet medical needs, focusing on areas such as virology and oncology. Its product portfolio includes treatments for HIV, viral hepatitis, and cancer, among others.
With a market capitalization of $148.06 billion and a P/E ratio of 18.26, Gilead continues to demonstrate strong financial health. The upcoming earnings report is scheduled for August 4, 2026, with EPS and revenue estimates of $2.22 and $7.6 billion, respectively. Investors may find additional context in the full earnings release and management commentary following the call.